11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts

Matthew Krebs; Margarita Majem; M. Forster; J.A. Peguero; Tonya Clay; E. Felip; Wade Iams; Patricia Roxburgh; B. Spéville; P. Bajaj; C. Mueller; F. Triebel

doi:10.1016/j.annonc.2022.02.020

11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts

Matthew Krebs, Margarita Majem, M. Forster, J.A. Peguero, Tonya Clay, E. Felip, Wade Iams, Patricia Roxburgh, B. Spéville, P. Bajaj, C. Mueller, F. Triebel

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S33
Journal	Annals of Oncology
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.02.020
Publication status	Published - 1 Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.02.020

Cite this

Krebs, M., Majem, M., Forster, M., Peguero, J. A., Clay, T., Felip, E., Iams, W., Roxburgh, P., Spéville, B., Bajaj, P., Mueller, C., & Triebel, F. (2022). 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. Annals of Oncology, 33, S33. https://doi.org/10.1016/j.annonc.2022.02.020

@article{a6b840ef81d649aa94e00e988ebc4398,

title = "11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts",

author = "Matthew Krebs and Margarita Majem and M. Forster and J.A. Peguero and Tonya Clay and E. Felip and Wade Iams and Patricia Roxburgh and B. Sp{\'e}ville and P. Bajaj and C. Mueller and F. Triebel",

year = "2022",

month = apr,

day = "1",

doi = "10.1016/j.annonc.2022.02.020",

language = "English",

volume = "33",

pages = "S33",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Krebs, M, Majem, M, Forster, M, Peguero, JA, Clay, T, Felip, E, Iams, W, Roxburgh, P, Spéville, B, Bajaj, P, Mueller, C & Triebel, F 2022, '11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts', Annals of Oncology, vol. 33, pp. S33. https://doi.org/10.1016/j.annonc.2022.02.020

11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. / Krebs, Matthew; Majem, Margarita; Forster, M. et al.
In: Annals of Oncology, Vol. 33, 01.04.2022, p. S33.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts

AU - Krebs, Matthew

AU - Majem, Margarita

AU - Forster, M.

AU - Peguero, J.A.

AU - Clay, Tonya

AU - Felip, E.

AU - Iams, Wade

AU - Roxburgh, Patricia

AU - Spéville, B.

AU - Bajaj, P.

AU - Mueller, C.

AU - Triebel, F.

PY - 2022/4/1

Y1 - 2022/4/1

U2 - 10.1016/j.annonc.2022.02.020

DO - 10.1016/j.annonc.2022.02.020

M3 - Meeting Abstract

SN - 0923-7534

VL - 33

SP - S33

JO - Annals of Oncology

JF - Annals of Oncology

ER -